A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Trial Profile

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=126) assessing safety and efficacy of ABT-414 with or without temozolomide in patients with recurrent glioblastoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top